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SUPPLEMENTARY METHODS  
Washington University in St. Louis (WUSTL). All human tissues acquired for 
experiments were processed in compliance with NIH regulations and institutional 
guidelines, as approved by the Institutional Review Board at WUSTL. All tumor 
materials from patients were obtained either via core needle biopsy, skin punch biopsy, 
or surgical resection after informed consent. All animal procedures were reviewed by 
and received ethical approval from the Institutional Animal Care and Use Committee at 
WUSTL. Pancreatic cancer models were derived from tissue fragments implanted 
subcutaneously into dorsal flank regions of 5-week-old non-humanized, female 
NOD/SCID/γ mice (Jackson Laboratory, Bar Harbor, ME) using Matrigel. Animal 
environments were maintained at 68-72°F and 45-55% relative humidity. The sample 
tissues for these PDX models were obtained from archived, cryopreserved PDX 
harvests. Final tumor passages in mice were kept cold and harvested into RPMI-1640 
with antibiotic and antimycotic additives. Patient tumors were obtained directly from 
operating rooms and placed into sterile collection media (RPMI-1640 with antibiotic and 
antimycotic additives). Pieces of each tumor were processed into the following forms: 
flash frozen tissue fragments, OCT blocks and matched haemotoxylin and eosin (H&E) 
slides, formalin fixed paraffin blocks (FFPE) and matched H&E slides, RNA later tissue 
storage, and cryopreserved fragments (FBS + 10% DMSO). A minimum of 250 mg of 
flash frozen material was submitted to the Siteman Cancer Center’s Proteomics Core. 
The tissues were cryo-pulverized and subsequently divided for DNA and RNA 
preparation and long-term storage. Parental genomic DNA was prepared from OCT 
blocks if available, and if not available, paraffin blocks were utilized. In addition, 
genomic DNA for sequencing control was prepared from peripheral blood mononuclear 
cells. Whole-exome sequencing was conducted as follows: Libraries were constructed 
using unamplified genomic DNA (minimum 100 ng) from blood (normal), tumor, and 
xenograft samples. Exons were captured via IDT Exome library kit followed by high-
throughput sequencing on an Illumina NovaSeq S4 platform (Illumina Inc., San Diego, 
CA) using 150bp paired-end reads. RNA-seq was performed using NovaSeq 6000 
sequencing system. 
 
National Cancer Institute Patient-Derived Models Repository (PDMR). Solid tumor 
specimens across histologies are collected from patients being evaluated for and/or 
treated for cancer at clinical centers across the United States under National Cancer 
Institute (NCI)-sponsored tissue procurement protocols with institutional review board 
approval. Exclusion criteria were limited to certain infections that would compromise 
either the ability to make or to distribute preclinical models by the NCI. Investigators 
obtained informed consent/assent from each participant for the use of their delinked 
specimens specifically to generate and genetically characterize animal models and cell 
cultures and to have these models made available to researchers along with limited 
information about their medical history, also delinked, through a public database 
(https://pdmr.cancer.gov/). Information about which clinical center and which 
investigator provided the specimen are not recorded. Models for distribution by NCI’s 
Patient-Derived Models Repository were generated at the Biological Testing Branch, 
DTP, NCI-Frederick. NCI-Frederick is accredited by the Association for Assessment and 
Accreditation of Laboratory Animal Care International and follows the Public Health 
Service (PHS) Policy on Humane Care and Use of Laboratory Animals. All studies were 
conducted on an approved NCI at Frederick Institutional Animal Care and Use 
Committee protocol in accordance with the procedures outlined in the “Guide for Care 
and Use of Laboratory Animals” (National Research Council; 2011; National Academy 
Press; Washington, DC). Mice were housed in sterile, filter-capped polycarbonate cages, 
maintained in a barrier facility on a 12-hour light/dark cycle, and were provided sterilized 
food and water, ad libitum. For engraftments, tumor material plus a drop of Matrigel (BD 
BioSciences, Bedford, MA) were implanted subcutaneously in NOD.Cg-Prkdcscid 
Il2rgtm1Wjl/SzJ (NSG) mice that are sex-matched to the human patient. Animals were 
monitored weekly for tumor growth. The initial passage of material was grown to 
approximately 1000-2000 mm3 calculated using the following formula: weight (mg) = 
(tumor length × [tumor width]2) / 2. Tumor material was then harvested, a portion 
cryopreserved, and the remainder implanted into NSG host mice. Every PDX tumor 
harvested and cryopreserved also had 2-3 fragments snap frozen for next generation 
sequence analysis and short tandem repeat validation, as well as a piece fixed in 
neutral buffered formalin and then embedded in paraffin for histological assessment. 
Full PDMR standard operating procedures for tumor engraftment and PDX passaging 
are available at https://pdmr.cancer.gov/sops. The whole-exome sequencing was 
conducted based on PDMR guidelines available online at 
https://pdmr.cancer.gov/content/docs/MCCRD_SOP0009_PDX_Illumina_Sequencing_li
brary_pools_external.pdf. The RNA-Seq library preparation and sequencing were 




The University of Texas MD Anderson Cancer Center (MDACC). Fresh non-small-
cell lung carcinoma tumor samples were collected from surgically resected specimens 
with the informed consent of the patients. The sex and race distributions of patients 
were similar to those of patient throughout the USA. Generation and passaging of PDXs, 
and histological analysis and DNA fingerprint assay for PDXs and their primary tumor 
tissues were performed as previously described 1,2 . Early PDXs were generated and 
passaged in 6-10 week-old NOD/SCID mice, while later PDXs were generated using 
NSG mice and then passaged solely in nude mice (80% success rate) or otherwise 
solely in NSG mice. Both male and female mice were used in the study. The protocols 
for the use of clinical specimens and data in this study were approved by the 
Institutional Review Board at The University of Texas MD Anderson Cancer Center. All 
animal studies were carried out in accordance with the Guidelines for the Care and Use 
of Laboratory Animals (National Institutes of Health Publication 85-23) and the 
institutional guidelines of MDACC. Mice were housed in 70-74°F rooms at 40-55% 
relative humidity. Whole-exome sequencing followed MDACC protocol 3. Equimolar 
amounts of DNA were pooled (2-6 samples per pool) and whole exome regions were 
captured by using biotin labeled probes from Roche Nimblegen (Exome V3) followed 
manufacturer’s protocol. The captured libraries were sequenced on a HiSeq 2000 with 
100bp paired-end (Illumina Inc., San Diego, CA, USA) on a paired-end flowcell.  
The WISTAR Institute (WISTAR). Tumor biopsy samples were collected with the 
informed, written consent of the patients according to a Wistar Institutional Review 
Board (IRB) approved protocol. Animal studies were carried out in accordance with the 
Wistar Animal Care and Use Program as overseen by The Wistar Institutional Animal 
Care and Use Committee (IACUC). The protocol to generate PDX models requires the 
subcutaneous implantation of fresh tissue from primary or metastatic melanomas 
(collected by biopsy or surgery) into NOD/SCID/IL2-receptor null (NSG) mice. Detailed 
preparation guidelines are given by Xiao et al. 4 and Krepler et al. 5 Whole exome 
sequencing was conducted as follows: Genome DNA extraction was done using Qiagen 
DNeasy Blood & Tissue Kit, and libraries for whole exome sequencing were performed 
using Nextera DNA exome kit. Capture libraries were amplified, pooled, and then 
sequenced on an Illumina HiSeq 2500 76bp paired-end run. Average coverage for 
normal samples was 97.50x (71.46 min – 124.64 max), and was 208.27x for tumor 
samples (146.88 min – 281.20 max). More details of the standard animal and genomics 
protocols of WISTAR is available at https://wistar.org/research-discoveries/shared-
resources/. 
Baylor College of Medicine (BCM). Human breast cancers were procured as stably 
transplantable xenografts previously established in SCID/Beige or NOD/SCID 
IL2Rgamma-null (NSG) immunocompromised mice 6, 7. PDX lines were maintained by 
serial transplantation into the inguinal mammary fat pad into 3-5 week-old female mice 
of the aforementioned strains using jeweler’s forceps via a 0.5 cm incision in the skin of 
the animal to expose the fat pad. Incisions were closed with a single staple and animals 
allowed to recover on a warming plate. Animal environments were maintained at 68-
72°F at 30-70% relative humidity under a 10:14 130-300 lux light cycle with standard 
breeding and regular diets provided. These xenografts represent the major clinically 
defined subtypes of breast cancer, e.g. estrogen receptor positive (ER+), HER2 positive 
(HER2+), and “triple negative” (TN) breast cancers. The detailed methods of 
implantation and strains were presented by Zhang and Lewis 8. For that work, breast 
cancer patients were recruited from clinics in the Baylor College of Medicine Breast 
Center and Ben Taub General Hospital under IRB-approved protocols, which included 
informed, written patient consent. For ER+ PDX lines, estradiol (8ug/ml) was provided in 
the drinking water. Animal care was in accordance with the NIH Guide for the Care and 
Use of Experimental Animals with approval from the Baylor College of Medicine 
Institutional Animal Care and Use Committee and in compliance with all relevant ethical 
regulations for animal testing and research. Preparation and generation of whole exome 
and RNA-Seq data were undertaken as previously reported 9, 10. 
Huntsman Cancer Institute (HCI). All tissue samples were collected with informed 
consent from individuals being treated at the Huntsman Cancer Hospital and the 
University of Utah under a protocol approved by the University of Utah Institutional 
Review Board. Samples were collected and de-identified by the Huntsman Cancer 
Institute Tissue Resource and Application Core facility before being obtained for 
implantation. Tumor processing, histology, and immunostaining were described by 
DeRose et al. 11 Animal husbandry was in accordance with the University of Utah and 
Animal Welfare Act, and all mouse studies were reviewed and approved by the 
University of Utah’s Office of Institutional Animal Care and Use Committee (IACUC). 
Detailed methods of implantation into 3- to 4-week-old female NOD/SCID mice are 
presented by DeRose et al. 11  and DeRose et al. 12. Details of sequencing methods 
were described by Ma et al., 2020 (doi: https://doi.org/10.1101/2020.06.25.172056) and 














Supplementary Fig. 1: a The number of models per cancer type for low similarity 
events.  Genetic alterations found in (b) 97 BRCA patients, and (c) 72 COADREAD 










Supplementary Fig. 2: a The dependence of unique cis and trans events on sample 
size for BLCA.  b The effects of RB1 mutations on the expression of CDK, CCNE, and 
MCM genes based on TCGA data. Sample numbers (n) for (WT, Mut) are (330, 76) for 
BLCA and (439, 26) for SKCM c The comparison of CDK, CCNE, and MCM gene 
expression between mutated and WT-type RB1 PDX samples. Sample numbers (n) for 
(WT, Mut) are (120, 20) for BLCA and (81,4) for SKCM. Source data are provided as a 
Source Data file. The box boundary of each box plot indicates third quartile and first 
quartile respectively from the top to bottom. The whisker on top were drawn out from the 
third quartile to the largest data point or up to 1.5 × IQR. Similarly, the bottom whisker 
extends from the first quartile down to 1.5 × IQR or the lowest data point.  The red dot at 







Supplementary Fig. 3: a Distribution of kinase fusions based on kinase locations (5’-
end, 3’-end, or as both fusion partners) and the in-frame status. b Median normalized 
expression of fusion involving oncogenes and tumor suppressor genes per cancer type. 
Fusion in greater than 2 PDX samples while overlap with TCGA events are shown. 






Supplementary Fig. 4: RNA expression for the top 1000 most variable genes in 4 PDX 
models (R2, R3, R4 and R6) from case PDMR-521955. Human tumor samples 
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Supplementary Fig. 5: Additional pan-cancer transcriptional group distribution on 2D 
UMAP. 2D UMAP distributions of (a) cancer groups, (b) collection center, (c) treatment 








Supplementary Fig. 6: Comparison of genetic alterations with DEPO and CIViC 
databases and estimation of arm coverages across PDX passages. a Percentage of 
known druggable gene alteration in PDX genetic alterations. ‘Yes’ and ‘Any’ mean that 
the alterations have known drugs, and ‘No’ means there are no known drugs that match 
with the genetic alterations. The Venn diagram presents that 76% genetic alterations 
matched with TCGA or COMIC (v90) database, and 24% genetic alterations belong to 
unknown alterations. b Display positive signals for the target arms via the percentage of 
PDX passages. Source data are provided as a Source Data file.  
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